NovoLog® (insulin aspart injection) 100 U/mL Mechanism of Action (7:39)

Discover how NovoLog® works in the system, in terms that can be used with your patients.


NovoLog® (insulin aspart injection) 100 U/mL Mechanism of Action (7:39)


Discover how NovoLog® works in the system, in terms that can be used with your patients.

Return to overview


Return to overview


1. NovoLog® [prescribing information]. Plainsboro, NJ: Novo
    Nordisk Inc; 2013.

2. Funnel MM. Overcoming barriers to the initiation of insulin
    therapy. Clin Diabetes. 2007;25(1):36-38.

3. Brange J, Volund A. Insulin analogs with improved
    pharmacokinetic profiles. Adv Drug Deliv Rev. 1999;35(2-

4. Liebl A, Prager R, Binz K, Kaiser M, Bergenstal R, Gallwitz
    B; for the PREFER Study Group. Comparison of insulin
    analogue regimens in people with type 2 diabetes mellitus
    in the PREFER Study: a randomized controlled
    trial. Diabetes Obes Metab. 2009;11(1):45-52.

5. Raskin P, Guthrie RA, Leiter L, Riis A, Jovanovic L. Use of
    insulin aspart, a fast-acting insulin analog, as the
    mealtime insulin in the management of patients
    with type 1 diabetes. Diabetes Care. 2000;23(5):

6. Lindholm A, McEwen J, Riis AP. Improved postprandial
    glycemic control with insulin aspart: a randomized double-
    blind cross-over trial in type 1 diabetes. Diabetes Care. 

7. Data on file. Novo Nordisk Inc, Princeton, NJ.

8. Heller SR, Colagiuri S, Vaaler S, et al. Hypoglycaemia
    with insulin aspart: a double-blind, randomised,
    crossover trial in subjects with type 1 diabetes. 
    Diabet Med. 2004;21(7):769-775.

9. Polonsky KS, Sturis J, Bell GI. Non insulin dependent
    diabetes mellitus - a genetically programmed failure
    of the beta cell to compensate for insulin resistance.
    N Engl J Med. 1996: 334(March 21):777-783.

10.Monnier L Lapinski H, Colette C. Contributions of
    fasting and postprandial plasma glucose increments
    to the overall diurnal hyperglycemia of type 2 diabetic
    patients: variations with increasing levels of HbA1c. 
    Diabetes Care. 2003;26(3):881-885.

11.Woerle HJ, Neurmann C, Zschau S, et al. Impact of
    fasting and postprandrial glycemia on overall glycemic
    control in type 2 diabetes: importance of postprandial
    glycemia to achieve target HbA1c levels. Diabetes Res
    Clin Pract. 2007;77(2):280-285.

Product Important Safety Information

NovoLog® (insulin aspart injection) 100 U/mL Indications and Usage

NovoLog® (insulin aspart injection) 100 U/mL is an insulin analog indicated to improve glycemic control in adults and children with diabetes mellitus.

Important Safety Information


  • NovoLog® is contraindicated during episodes of hypoglycemia and in patients hypersensitive to NovoLog® or one of its excipients.

Warnings and Precautions

  • Never Share a NovoLog® FlexPen, NovoLog® FlexTouch®, PenFill® Cartridge, or PenFill® Cartridge Device Between Patients, even if the needle is changed. Patients using NovoLog® vials must never share needles or syringes with another person. Sharing poses a risk for transmission of blood-borne pathogens. 
  • Changes in insulin strength, manufacturer, type, or method of administration may affect glycemic control and predispose to hypoglycemia or hyperglycemia. These changes should be made cautiously under close medical supervision and the frequency of blood glucose monitoring should be increased. 
  • Hypoglycemia is the most common adverse effect of insulin therapy. The timing of hypoglycemia may reflect the time-action profile of the insulin formulation. Glucose monitoring is recommended for all patients with diabetes and is particularly important for patients using external pump infusion therapy. 
  • To avoid medication errors and accidental mix-ups between NovoLog® and other insulin products, instruct patients to always check the insulin label before injection. 
  • Severe, life-threatening, generalized allergy, including anaphylaxis, may occur with insulin products, including NovoLog®
  • As with all insulins, NovoLog® use can lead to life-threatening hypokalemia, which then may cause respiratory paralysis, ventricular arrhythmia, and death.  Monitor potassium levels in patients at risk for hypokalemia and treat if indicated.
  • Fluid retention and heart failure can occur with concomitant use of thiazolidinediones (TZDs), which are PPAR-gamma agonists, and insulin, including NovoLog®. Patients should be observed for signs and symptoms of heart failure. If heart failure occurs, dosage reduction or discontinuation of the TZD must be considered. 
  • Malfunction of the insulin pump or insulin infusion set or insulin degradation can rapidly lead to hyperglycemia and ketoacidosis. Patients using insulin infusion pump therapy must be trained to administer insulin by injection and have alternate insulin therapy available in case of pump failure. 

NovoLog® continuous subcutaneous infusion route (insulin pump): Do not mix NovoLog® with any other insulin or diluent. 

Adverse Reactions

  • Adverse reactions observed with NovoLog® include hypoglycemia, allergic reactions, local injection site reactions, lipodystrophy, rash, and pruritus.

Use in Specific Populations

  • NovoLog® has not been studied in children with type 2 diabetes or in children with type 1 diabetes who are younger than 2 years of age. 
  • Like all insulins, NovoLog® requirements may be reduced in patients with renal impairment or hepatic impairment. These patients may require more frequent blood glucose monitoring and dose adjustments. 

Please click here for Prescribing Information.